Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene

Ann Hematol. 2015 Nov;94(11):1927-8. doi: 10.1007/s00277-015-2451-7. Epub 2015 Jul 23.

Authors

Elisa Rumi¹, Jelena D Milosevic², Dominik Selleslag³, Ilaria Casetti⁴, Els Lierman⁵, Daniela Pietra⁶, Chiara Cavalloni⁴, Marta Bellini⁴, Chiara Milanesi⁶, Irene Dambruoso⁶, Cesare Astori⁶, Robert Kralovics^{2

7}, Peter Vandenberghe⁵, Mario Cazzola^{6

4}

Affiliations

¹ Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy. elisarumi@hotmail.com.
² CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
³ AZ Sint-Jan, Brugge, Belgium.
⁴ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
⁵ Center for Human Genetics, KU Leuven/University Hospital Leuven, Leuven, Belgium.
⁶ Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100, Pavia, Italy.
⁷ Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria.

PMID: 26202607
DOI: 10.1007/s00277-015-2451-7

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Female
Humans
Hypereosinophilic Syndrome / drug therapy*
Hypereosinophilic Syndrome / genetics
Leukemia
Male
Myeloproliferative Disorders / drug therapy*
Myeloproliferative Disorders / genetics
Nitriles
Oncogene Proteins, Fusion / genetics*
Pyrazoles / therapeutic use*
Pyrimidines
Remission Induction
Treatment Outcome

Substances

Nitriles
Oncogene Proteins, Fusion
PCM1-JAK2 fusion protein, human
Pyrazoles
Pyrimidines
ruxolitinib

Supplementary concepts

Pdgfra-Associated Chronic Eosinophilic Leukemia